Young Non-Smokers Fall Through Lung Cancer Screening Gap

Rasika Bombatkar was 34 when she learned she had lung cancer. She had never smoked. She was fit. She had no family history of the disease. By the time a doctor took her symptoms seriously enough to order imaging, the cancer had already spread to her lymph nodes. She was at stage 3b.

Her case exposes a systemic failure in how the world screens for lung cancer. The dominant medical narrative—reinforced by decades of research, public health campaigns, and clinical guidelines—holds that lung cancer is a disease of older people with long smoking histories. Screening programmes, including the gold-standard Low Dose Computer Tomography (LDCT), are designed around this profile. They target people between 50 and 80 years old who have smoked a pack a day for at least 20 to 30 years. The logic is sound from a public health efficiency standpoint: LDCT involves radiation exposure that itself carries cancer risk, so screening is reserved for populations where the benefit clearly outweighs that harm. But the logic has a blind spot. It assumes that the people most likely to benefit from screening are the only people who need it.

In India, the numbers tell a different story. Lung cancer was the third most common cancer in 2024, affecting 112,000 people and killing more than 98,000. It accounted for 7.2 percent of all cancers but 10.9 percent of cancer deaths—a disproportionate toll. A study of India's cancer registries found that nearly 45 percent of patients were diagnosed only after the disease had spread, when treatment becomes harder and survival odds plummet. In Hong Kong and other parts of Asia, more than half of lung cancer cases occur in people without smoking histories. Yet screening guidelines remain anchored to the smoker profile, leaving younger non-smokers to navigate a medical system that does not expect to find them.

Bombatkar spoke about her experience at the World Cancer Congress in Hong Kong in September 2026, where global cancer experts gathered to examine how screening could be made more effective without simply expanding it to entire populations. "All the medical literature stating that the disease usually happens at a later age, among people who have been smoking for years, means that even doctors do not suspect it in the young," she told The Indian Express. "But the reality is that people like me also get the disease and the doctors should at least review such decisions when symptoms are present." The problem is not just diagnostic delay. It is the weight of assumption. When a young non-smoker presents with persistent cough or chest pain, a doctor trained to think of lung cancer as a smoker's disease may order tests for other conditions first, or dismiss the symptoms as anxiety or infection. By the time imaging happens, the disease has progressed.

Even after diagnosis, Bombatkar found herself having to justify her own illness. "All the campaigns against tobacco smoking warn of lung cancer. But in doing so, it makes people think that the people who get the disease deserve it," she said. Relatives and neighbours discouraged her from speaking publicly about her condition. The stigma attached to lung cancer—the assumption that it is a self-inflicted consequence of smoking—extends to those who never smoked at all, as if the disease itself is somehow less legitimate.

Experts at the World Cancer Congress acknowledged the gap. Dorothy Keefe, CEO of Cancer Australia, noted that when researchers examined whether lung cancer screening would be cost-effective in Australia, they found that most cases occurred among long-term smokers, which shaped the population selected for screening. But in Asia, the epidemiology is different. Dr Anne Lee, vice chairman of the Hong Kong Anti-Cancer Society, said that Hong Kong is studying whether screening could benefit high-risk non-smokers, including those with a family history of lung cancer. Béatrice Lauby-Secretan, who heads the International Agency for Research on Cancer's work in this area, suggested that emerging risk-prediction models could help identify people outside traditional screening criteria—incorporating exposure to air pollution, second-hand smoke, and occupational hazards. Indian researchers at the All-India Institute of Medical Sciences are examining whether living in highly polluted areas accelerates lung cancer risk.

But identifying who needs screening is only part of the problem. Bombatkar's path to treatment revealed another set of barriers. After diagnosis, she needed molecular testing to determine whether she carried mutations that would make her eligible for targeted therapies. The test cost between Rs 50,000 and Rs 1 lakh—roughly $600 to $1,200. When her results showed she could benefit from osimertinib, a targeted drug, the monthly cost was Rs 1 lakh. Her salary was Rs 35,000 a month. She could not afford it. Clinical trials offered another route, but they accepted patients only up to stage 3a. She was 3b. She was ineligible.

She did what many Indian patients are forced to do: she bought an unbranded version of the drug manufactured in Bangladesh, where patent rules allow certain flexibilities for lower-middle-income countries. It cost Rs 25,000 a month—still a strain on her family, who considered selling property to help pay for treatment. "I did not know whether the drug worked the same way as the branded version," she said. "The only way to tell that something was happening was to watch out for side effects." After surgery to remove part of her lung and multiple rounds of treatment, she has managed to push the disease back. But the experience left her acutely alert to every symptom, and determined to speak publicly so that other patients who do not fit the traditional profile know they are not alone and should trust their bodies when something feels wrong.